Match!
Quentin M. Anstee
Newcastle University
235Publications
41H-index
6,187Citations
Publications 237
Newest
Abstract Background Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways involved in NASH. Design TANDEM (CLJC242A2201J; NCT03517540 ) is a 48-week, phase 2b, randomized, double-blind, multicenter study in 200 adult patients with b...
Source
Summary Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease...
2 CitationsSource
#1Quentin M. Anstee (Newcastle University)H-Index: 41
#2E.J. Lawitz (University of Texas at Austin)H-Index: 34
Last.Zobair M. Younossi (Inova Fairfax Hospital)H-Index: 84
view all 25 authors...
3 CitationsSource
#1Zobair M. Younossi (Inova Health System)H-Index: 84
#2Maria StepanovaH-Index: 36
Last.Stephen A. Harrison (University of Oxford)H-Index: 26
view all 15 authors...
Background Patient-reported outcomes (PROs) are used to measure patients’ experience with their disease. However, there are few PRO data from patients with NASH. We collected data from the STELLAR clinical trials to assess PROs for NASH and advanced fibrosis. Methods We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selons...
1 CitationsSource
#1Feng Liu (PKU: Peking University)H-Index: 9
#2George Boon-Bee Goh (SGH: Singapore General Hospital)H-Index: 5
Last.Lai Wei (PKU: Peking University)H-Index: 1
view all 19 authors...
Source
#1Mary Eugenia Rinella (NU: Northwestern University)H-Index: 25
#2Frank Tacke (Charité)H-Index: 3
Last.Quentin M. Anstee (Newcastle University)H-Index: 41
view all 4 authors...
Summary Non-alcoholic fatty liver disease (NAFLD) is a global public health concern. Its natural history, the development of non-alcoholic steatohepatitis (NASH) and fibrosis, is highly variable, prone to endogenous ( e.g. , genetics, microbiota) and exogenous ( e.g. , nutrition, alcohol, physical activity) disease modifiers, and can fluctuate over time. The complexity of its pathophysiology is reflected by the multitude of pharmacological targets in development. NASH clinical trials have provid...
1 CitationsSource
Source
Source
#1Mary Eugenia Rinella (NU: Northwestern University)H-Index: 25
#2Frank Tacke (Charité)H-Index: 3
Last.Quentin M. Anstee (Newcastle University)H-Index: 41
view all 4 authors...
2 CitationsSource
#1Yvonne Huber (University of Mainz)H-Index: 4
#2Marie Boyle (Newcastle University)H-Index: 4
Last.Jörn M. Schattenberg (University of Mainz)H-Index: 23
view all 11 authors...
Background & Aims Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL. Methods We collected data from 304 patients (mean age, 52.3 ± 12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed wit...
4 CitationsSource
12345678910